[1] GONG X，ZOU X，LIU L，et al. Prognostic value

of inflammatory mediators in 1-year outcome of

acute ischemic stroke with middle cerebral artery

stenosis[J/OL]. Mediators Inflamm，2013，2013：

850714. https：//doi.org/10.1155/2013/850714.

[2] LI J，WANG Y，LIN J，et al. Soluble CD40L is a

useful marker to predict future strokes in patients

with minor stroke and transient ischemic attack[J].

Stroke，2015，46（7）：1990-1992.

[3] LIN J，ZHENG H，CUCCHIARA B L，et al.

Association of Lp-PLA2-A and early recurrence

of vascular events after TIA and minor stroke[J].

Neurology，2015，85（18）：1585-1591.

[4] MULLEN M T，MESSE S R，KASNER S E，et al.

Anti-Phosphatidylserine-Prothrombin Antibodies

are Associated with Outcome in a TIA Cohort[J/OL].

Front Neurol，2012，3：137. https：//doi.org/10.3389/

fneur.2012.00137.

[5] GREISENEGGER S，SEGAL H C，BURGESS A

I，et al. Biomarkers and mortality after transient

ischemic attack and minor ischemic stroke：

Population-based study[J]. Stroke，2015，46（3）：

659-666.

[6] LI J，WANG Y，WANG D，et al. Glycated albumin

predicts the effect of dual and single antiplatelet

therapy on recurrent stroke[J]. Neurology，2015，84

（13）：1330-1336.

[7] LIU L，WONG K S，LENG X，et al. Dual

antiplatelet therapy in stroke and ICAS：Subgroup

analysis of CHANCE[J]. Neurology，2015，85（13）：

1154-1162.

[8] JOHNSTON S C，AMARENCO P，ALBERS G

W，et al. Ticagrelor versus aspirin in acute stroke or

transient ischemic attack[J]. N Engl J Med，2016，375

（14）：1395.

[9] WANG Y，ZHAO X，LIN J，et al. Association

Between CYP2C19 Loss-of-Function Allele Status

and Efficacy of Clopidogrel for Risk Reduction

Among Patients With Minor Stroke or Transient

Ischemic Attack[J]. JAMA，2016，316（1）：70-78.

[10] WALLENTIN L，BECKER R C，BUDAJ A，et al.

Ticagrelor versus clopidogrel in patients with acute

coronary syndromes[J]. N Engl J Med，2009，361

（11）：1045-1057.

[11] WANG Y，LIN Y，MENG X，et al. Effect of

ticagrelor with clopidogrel on high on-treatment

platelet reactivity in acute stroke or transient

ischemic attack（PRINCE）trial：Rationale and

design[J]. Int J Stroke，2017，12（3）：321-325.

[12] WIVIOTT S D，ANTMAN E M，WINTERS K J，et al. Randomized comparison of prasugrel（CS-

747，LY640315），a novel thienopyridine P2Y12

antagonist，with clopidogrel in percutaneous

coronary intervention：results of the Joint Utilization

of Medications to Block Platelets Optimally

(JUMBO)-TIMI 26 trial[J]. Circulation，2005，111

（25）：3366-3373.

[13] EZEKOWITZ M D，REILLY P A，NEHMIZ G，et

al. Dabigatran with or without concomitant aspirin

compared with warfarin alone in patients with nonvalvular atrial fibrillation（PETRO Study）[J].

Am J Cardiol，2007，100（9）：1419-1426.

[14] CONNOLLY S J，EZEKOWITZ M D，YUSUF S，et

al. Dabigatran versus warfarin in patients with atrial

fibrillation[J]. N Engl J Med，2009，361（12）：1139-

1151.

[15] PATEL M R，MAHAFFEY K W，GARG J，et al.

Rivaroxaban versus warfarin in nonvalvular atrial

fibrillation[J]. N Engl J Med，2011，365（10）：883-

891.